Enos
Enos | |
---|---|
Synonyms | N/A |
Pronounce | N/A |
Specialty | N/A |
Symptoms | |
Complications | |
Onset | |
Duration | |
Types | N/A |
Causes | |
Risks | |
Diagnosis | |
Differential diagnosis | |
Prevention | N/A |
Treatment | |
Medication | |
Prognosis | |
Frequency | |
Deaths | N/A |
Enos is a term that may refer to a specific condition or context within the field of medicine, particularly related to cardiology. It is important to clarify the context in which "Enos" is used, as it may not be a widely recognized medical term on its own. This article will explore potential meanings and contexts where "Enos" might be relevant, particularly focusing on its relation to endothelial nitric oxide synthase (eNOS), a critical enzyme in cardiovascular health.
Endothelial Nitric Oxide Synthase (eNOS)[edit | edit source]
Overview[edit | edit source]
Endothelial nitric oxide synthase (eNOS) is one of the three isoforms of the enzyme nitric oxide synthase (NOS), which is responsible for the production of nitric oxide (NO) in the body. NO is a crucial signaling molecule involved in various physiological processes, including vascular tone regulation, blood pressure control, and immune response.
Function[edit | edit source]
eNOS is primarily expressed in endothelial cells, which line the interior surface of blood vessels. The enzyme catalyzes the conversion of L-arginine to NO and L-citrulline. The NO produced by eNOS diffuses into the surrounding smooth muscle cells, causing vasodilation and thus playing a key role in maintaining vascular homeostasis.
Regulation[edit | edit source]
The activity of eNOS is regulated by several factors, including:
- Calcium/calmodulin binding
- Phosphorylation at specific serine and threonine residues
- Interaction with other proteins such as caveolin-1 and heat shock protein 90 (Hsp90)
- Availability of cofactors like tetrahydrobiopterin (BH4)
Clinical Significance[edit | edit source]
Dysfunction of eNOS is implicated in various cardiovascular diseases, including hypertension, atherosclerosis, and heart failure. Reduced NO production or bioavailability can lead to endothelial dysfunction, a precursor to these conditions.
Pathophysiology[edit | edit source]
Endothelial Dysfunction[edit | edit source]
Endothelial dysfunction is characterized by a reduced ability of the endothelium to produce NO, leading to impaired vasodilation. This condition is often associated with risk factors such as hyperlipidemia, diabetes mellitus, smoking, and obesity.
Atherosclerosis[edit | edit source]
In atherosclerosis, the impaired function of eNOS contributes to the development of plaque formation within the arterial walls. The reduced NO levels lead to increased oxidative stress and inflammation, promoting the progression of atherosclerotic lesions.
Therapeutic Implications[edit | edit source]
Pharmacological Interventions[edit | edit source]
Several therapeutic strategies aim to enhance eNOS activity or NO bioavailability, including:
- Statins: These drugs not only lower cholesterol levels but also improve endothelial function by upregulating eNOS expression.
- ACE inhibitors and ARBs: These medications help improve endothelial function and reduce blood pressure.
- L-arginine supplementation: As a substrate for eNOS, L-arginine supplementation may enhance NO production.
Lifestyle Modifications[edit | edit source]
Lifestyle changes such as regular exercise, a heart-healthy diet, and smoking cessation can improve endothelial function and enhance eNOS activity.
Conclusion[edit | edit source]
Understanding the role of eNOS in cardiovascular health is crucial for developing effective strategies to prevent and treat cardiovascular diseases. Ongoing research continues to explore new ways to modulate eNOS activity and improve endothelial function.
Cardiovascular disease A-Z
Most common cardiac diseases
- Cardiac arrhythmia
- Cardiogenetic disorders
- Cardiomegaly
- Cardiomyopathy
- Cardiopulmonary resuscitation
- Chronic rheumatic heart diseases
- Congenital heart defects
- Heart neoplasia
- Ischemic heart diseases
- Pericardial disorders
- Syndromes affecting the heart
- Valvular heart disease
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
A[edit source]
- Accelerated idioventricular rhythm
- Acute decompensated heart failure
- Arteriosclerotic heart disease
- Athletic heart syndrome
- Atrial flutter
- Atrioventricular fistula
- Cardiovascular disease in Australia
- Autoimmune heart disease
B[edit source]
C[edit source]
- Ebb Cade
- Cardiac allograft vasculopathy
- Cardiac amyloidosis
- Cardiac asthma
- Cardiac tamponade
- Cardiogenic shock
- Cardiogeriatrics
- Cardiorenal syndrome
- Cardiotoxicity
- Carditis
- Coronary artery aneurysm
- Coronary artery anomaly
- Coronary artery disease
- Spontaneous coronary artery dissection
- Coronary artery ectasia
- Coronary occlusion
- Coronary steal
- Coronary thrombosis
- Coronary vasospasm
- Cœur en sabot
- Coxsackievirus-induced cardiomyopathy
D[edit source]
E[edit source]
H[edit source]
- Heart attack
- Heart failure
- Heart failure with preserved ejection fraction
- Heart to Heart (1949 film)
- High-output heart failure
- Hyperdynamic precordium
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
I[edit source]
- Idiopathic giant-cell myocarditis
- Interventricular dyssynchrony
- Intraventricular dyssynchrony
- Isolated atrial amyloidosis
K[edit source]
L[edit source]
M[edit source]
- Mydicar
- Myocardial bridge
- Myocardial disarray
- Myocardial rupture
- Myocardial scarring
- Myocardial stunning
- Myocarditis
N[edit source]
O[edit source]
P[edit source]
- Papillary fibroelastoma
- Pathophysiology of heart failure
- Postpericardiotomy syndrome
- Pulmonary vein stenosis
R[edit source]
S[edit source]
- Saturated fat and cardiovascular disease
- SCAR-Fc
- Shone's syndrome
- Strain pattern
- Subacute bacterial endocarditis
- Sudden cardiac death of athletes
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
T[edit source]
V[edit source]
W[edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD